Health research network TriNetX has launched a Covid-19 Rapid Response Network to enable the pharmaceutical community to design clinical trials using real-world data (RWD).
The network is designed to quickly engage healthcare organisations with eligible patients who have confirmed an interest in receiving the Covid-19 clinical trial.
TriNetX said that the research network comprises clinical data from over 20,000 patients tested positive with coronavirus in the US and Europe.
Since its launch, seven clinical trials involving treatments and vaccines have been presented to the healthcare organisations within the network.
TriNetX Clinical Sciences vice-president Jennifer Stacey said: “Being able to provide access to up-to-date Covid-19 clinical data to researchers quickly is crucial since the world is depending on clinical trials to find ways to treat this disease.
“Our Rapid Response Network enables the pharmaceutical community to connect with healthcare organisations in minutes and hours rather than in weeks and months it would otherwise take through traditional processes.”
Global CRO Synteract has utilised the Covid-19 Rapid Response Network to identify study sites in Europe for a critical investigational medicinal product for coronavirus.
The CRO was able to engage all of the required study sites for the clinical trial within a week.
Synteract Global Operations vice-president Mary Mattes said: “The ability to quickly model an eligible patient cohort with real-world data and then be directed to the healthcare organisations where these Covid-19 patients are being treated enables us to quickly initiate life-saving clinical trials.”
The TriNetX platform includes a feature called Trial Connect, which enables the pharmaceutical community to engage clinical trial offices at healthcare organisations with key trial opportunities for Covid-19 patients.
Last month, TriNetX partnered with Medical Data Vision (MDV), a provider of a health claims and administrative data from more than 400 acute hospitals in Japan.